Ardelyx’s Ibsrela wins FDA approval for IBS-C

04:51 EDT 13 Sep 2019 | Pharmafile

Ardelyx announced that it has received FDA approval for its NHE3 sodium transport inhibitor Isbrela (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

Isbrela is a 50mg, twice daily oral pill that is a minimally absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3, resulting in an increase in bowel movements and a decrease in abdominal pain for IBS-C patients.

read more

Original Article: Ardelyx’s Ibsrela wins FDA approval for IBS-C


More From BioPortfolio on "Ardelyx’s Ibsrela wins FDA approval for IBS-C"

Quick Search

Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Irritable Bowel Syndrome IBS
Irritable bowel syndrome (IBS) is a common but poorly understood chronic (long-term) condition where the normal functions of the bowel are disrupted. Symptoms of IBS include abdominal pain or discomfort, changes in bowel habits and bloated feelings. ...